Periodic Reporting for period 1 - Dycare (Dynamic Care Solutions for clinical assessment of musculoskeletal and neurological disorders)
Reporting period: 2016-06-01 to 2016-11-30
60% of patients with MSD’s are misdiagnosed and are prescribed an ineffective rehabilitation program that delays or prevents their full recovery. A number of clinicians have confirmed this to us stating that they do not have the tools to measure movement conditions in an objective and reliable way.
Although there are solutions available that can aid in diagnosing and treating MSD’s, they do not match the needs of clinicians and health centres.
The reasons as to why health centres are looking for a new solution are multiple as current systems on the market: are prohibitively expensive for healthcare budgets; are non-portable with fixed cameras and equipment; are complex requiring highly skilled personnel to operate and interpret results; take a long time to set up; do not comply with medical device standards; are not interoperable with existing health centre equipment and patient information systems; are stand-alone products that cannot be upgraded with new wearables and features.
We aim to deliver an advanced solution to support the diagnosis and treatment phases for patients suffering from musculoskeletal disabilities resulting in: a better quality of life, a quicker return to work, and a reduction in costs for healthcare centres.
These objectives of the DyCare project will allow us to achieve the impacts of reducing MSD rehabilitation costs per patient by 10% annually and cutting temporary disability for these patients from an average of 60 days to 25 days a year by 2022.
- Quality management system certification related to the standards ISO13485 and ISO9001
- Registration of the DyCare brand at European level
- Preliminary freedom to operate
- Technical validation of the first product against other “gold standard” technologies
- Signing of valuable collaboration agreements with centres and institutions of the rehabilitation and academic sector.
Through the different interviews conducted with several stakeholders in different countries, the needs of the market and our initial hypothesis have been confirmed. However, thanks to the feedback obtained, we have perceived a new opportunity, defining a new concept of the product with a disruptive business model allowing access to a greater number of people to benefit from our solution.
We will provide to clinicians and patients with a new measurement and control system that improves the diagnosis and treatment of musculoskeletal and neurological disorders.